MRTX Stock Crashes As Amgen Rivalry Heats Up With New Lung Cancer Data

Mirati Therapeutics (MRTX) said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed Tuesday as investors questioned whether it could take on traditional chemotherapy.


The biotech company tested its drug, adagrasib, in combination with Merck‘s (MRK) Keytruda in patients with non small-cell lung cancer. Across all patients, 49% responded. In comparison, the standard combo of Keytruda plus chemo leads to a 48% overall response rate, SVB Securities…

Read More